Danaher Corp
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher COVID-19 Testing & Vaccines/Therapeutics Demand Impact by Quarter
COVID-19 Testing & Vaccines/Therapeutics Demand Impact (Legacy FY2021Q4–FY2023Q3) (%)
Danaher COVID-19 Testing & Vaccines/Therapeutics Demand Impact: 10.0% in Q3 2023, up 4.5 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2023 figure comes from
Source: Danaher IR — nongaap_ex_veralto ↗
Historical (Legacy) series through the Q3 2023 break (prior to discontinuing the separate breakout of COVID-19).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Testing & Vaccines/Therapeutics Demand Impact (Legacy FY2021Q4–FY2023Q3) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 10.0% | +4.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | 11.0% | +6.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | 12.0% | +10.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 6.5% | +22.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 5.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 5.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 1.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | -16.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
Cite this data
StockData. (2026). Danaher COVID-19 Testing & Vaccines/Therapeutics Demand Impact (%), quarterly Q4 2021–Q3 2023 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/covid-impact-legacy-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.